Literature DB >> 7523110

Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition.

I Hoffmann1, G Draetta, E Karsenti.   

Abstract

Progression through the cell cycle is monitored at two major points: during the G1/S and the G2/M transitions. In most cells, the G2/M transition is regulated by the timing of p34cdc2 dephosphorylation which results in the activation of the kinase activity of the cdc2-cyclin B complex. The timing of p34cdc2 dephosphorylation is determined by the balance between the activity of the kinase that phosphorylates p34cdc2 (wee1 in human cells) and the opposing phosphatase (cdc25C). Both enzymes are regulated and it has been shown that cdc25C is phosphorylated and activated by the cdc2-cyclin B complex. This creates a positive feed-back loop providing a switch used to control the onset of mitosis. Here, we show that another member of the human cdc25 family, cdc25A, undergoes phosphorylation during S phase, resulting in an increase of its phosphatase activity. The phosphorylation of cdc25A is dependent on the activity of the cdc2-cyclin E kinase. Microinjection of anti-cdc25A antibodies into G1 cells blocks entry into S phase. These results indicate that the cdc25A phosphatase is required to enter S phase in human cells and suggest that this enzyme is part of an auto-amplification loop analogous to that described at the G2/M transition. We discuss the nature of the in vivo substrate of the cdc25A phosphatase in S phase and the possible implications for the regulation of S phase entry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523110      PMCID: PMC395357          DOI: 10.1002/j.1460-2075.1994.tb06750.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  53 in total

1.  A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells.

Authors:  A Giordano; P Whyte; E Harlow; B R Franza; D Beach; G Draetta
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

2.  Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog.

Authors:  P Russell; P Nurse
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

3.  Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2.

Authors:  K Sadhu; S I Reed; H Richardson; P Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate.

Authors:  G Draetta; H Piwnica-Worms; D Morrison; B Druker; T Roberts; D Beach
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

5.  Performance of an automated system for capillary microinjection into living cells.

Authors:  W Ansorge; R Pepperkok
Journal:  J Biochem Biophys Methods       Date:  1988-08

6.  Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis.

Authors:  A O Morla; G Draetta; D Beach; J Y Wang
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

7.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

8.  Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle.

Authors:  J Gautier; T Matsukawa; P Nurse; J Maller
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

9.  Automatic microinjection system facilitates detection of growth inhibitory mRNA.

Authors:  R Pepperkok; M Zanetti; R King; D Delia; W Ansorge; L Philipson; C Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

10.  Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase.

Authors:  T Izumi; J L Maller
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

View more
  117 in total

1.  CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.

Authors:  E Vigo; H Müller; E Prosperini; G Hateboer; P Cartwright; M C Moroni; K Helin
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression.

Authors:  X Chen; R Prywes
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

3.  Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway.

Authors:  E Santoni-Rugiu; J Falck; N Mailand; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 4.  Cdc25 as a potential target of anticancer agents.

Authors:  J W Eckstein
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

5.  The kinetic origins of the restriction point in the mammalian cell cycle.

Authors:  B D Aguda; Y Tang
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

6.  Cdc25B functions as a novel coactivator for the steroid receptors.

Authors:  Z Q Ma; Z Liu; E S Ngan; S Y Tsai
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 7.  Cyclin/Cdk complexes: their involvement in cell cycle progression and mitotic division.

Authors:  P C John; M Mews; R Moore
Journal:  Protoplasma       Date:  2001       Impact factor: 3.356

8.  Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site.

Authors:  S N Dalal; C M Schweitzer; J Gan; J A DeCaprio
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

9.  Widdrol activates DNA damage checkpoint through the signaling Chk2-p53-Cdc25A-p21-MCM4 pathway in HT29 cells.

Authors:  Hee Jung Yun; Sook Kyung Hyun; Jung Ha Park; Byung Woo Kim; Hyun Ju Kwon
Journal:  Mol Cell Biochem       Date:  2011-12-11       Impact factor: 3.396

10.  Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

Authors:  Rozita Bagheri-Yarmand; Angela Nanos-Webb; Anna Biernacka; Tuyen Bui; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.